http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
High Sensitivity C-reactive Protein을 이용하여 분석한 전신 염증과 단기간 저용량 Cyclosporine의 건선 치료효과의 상관관계
정택조 ( Taek Jo Jeong ),신민경 ( Min Kyung Shin ),김낙인 ( Nack In Kim ) 대한피부과학회 2010 대한피부과학회지 Vol.48 No.3
Background: Cyclosporine is an immunosuppressant that acts on T-cells and cytokines. Although the efficacy of systemic cyclosporine in the treatment of psoriasis has been established, the relationship between response to cyclosporine and systemic inflammation using the high sensitivity C-reactive protein (hs-CRP) immunoassay is still unclear. Objective: The aim of this study is to investigate whether systemic inflammation with clinical and laboratory findings indicate a response after 8 weeks of oral 3 mg/kg cyclosporine therapy in patients with psoriasis. Methods: Thirty-five patients with psoriasis were treated with oral cyclosporine for 8 weeks. The clinical response to oral cyclosporine was determined using the PASI score. The correlation between hs-CRP and the treatment response to cyclosporine was analyzed. Also, descriptive characteristics of psoriatic patients with psoriatic arthritis, metabolic syndrome, and high BMI (BMI≥25) were investigated. Results: Hs-CRP levels and PASI scores were significantly reduced after 8 weeks of oral cyclosporine treatment. Eight patients showed excellent response, fifteen a good response, and twelve a moderate response. The baseline hs-CRP levels in excellent and good response groups (1.35±0.59 mg/L and 1.32±0.86 mg/L, respectively) to oral cyclosporine were significantly higher than the moderate response group (0.51±0.20 mg/L, p=0.004). Psoriatic patients with psoriatic arthritis, metabolic syndrome, and high BMI demonstrated higher levels of baseline hs-CRP. Patients with psoriatic arthritis and metabolic syndrome showed greater response to cyclosporine treatment. Conclusion: Patients with greater inflammatory burden, as demonstrated by elevated baseline hs-CRP, have better treatment responses to cyclosporine compared to patients with lesser inflammation. (Korean J Dermatol 2010; 48(3):171~178)
결절성 병변과 반피부위축증양 병변을 함께 보인 융기피부섬유육종
정택조 ( Taek Jo Jeong ),신민경 ( Min Kyung Shin ),이무형 ( Mu Hyoung Lee ) 대한피부과학회 2009 대한피부과학회지 Vol.47 No.3
Atrophic dermatofibrosarcoma protuberans (DFSP) is an uncommon clinical variant, which clinically mimics other atrophic dermatological conditions. Given the typical `protuberant` morphology of DFSP, such atrophic lesions may be difficult to diagnose clinically. We report a 44-year-old man who presented with an 8-month history of an asymptomatic, depressed, anetoderma-like plaque on the right subclavicular area. He also presented with a 1-year history of a 1.5×1.5 cm, asymptomatic, firm, erythematous nodule above an atrophic lesion. Biopsy specimens were taken from each lesion. These specimens, along with histochemical staining for CD34, established the diagnosis of dermatofibrosarcoma protuberans. (Korean J Dermatol 2009;47(3):361∼364)
Sunitinib에 의해 발생한 수족증후군과 수포성 고정약진 1예
정택조 ( Taek Jo Jeong ),이은주 ( Eun Ju Lee ),정기헌 ( Ki Heon Jeong ),신민경 ( Min Kyung Shin ),김낙인 ( Nack In Kim ) 대한피부과학회 2009 대한피부과학회지 Vol.47 No.6
Sunitinib is multitargeted tyrosine kinase inhibitor, and this drug was approved for use to treat gastrointestinal stromal tumor and advanced renal cell carcinoma. It has also been shown to be efficacious in treating neuroendocrine, colon and breast cancer. Sunitinib therapy is often complicated by cutaneous adverse effects such as hand-foot syndrome, hair depigmentation, subungal splinter hemorrhage, xerosis, alopecia and seborrheic dermatitis-like reactions. But there have been no reports on patients presenting with a bullous fixed drug eruption associated with sunitinib administration. We report here on a case of a bullous fixed drug eruption and hand-foot syndrome, and these maladies were caused by this agent. (Korean J Dermatol 2009;47(6):739∼742)
Aprotinin을 투여한 개심술 환자에서 Kaolin과 Celite Activator를 이용한 Activated Coagulation Time(ACT) 측정의 비교
김정택,선경,이춘수,백완기,조상록,김현태,김혜숙,박현희,김광호,Kim, Joung-Taek,Sun, Kyung,Lee, Choon-Soo,Baik, Wan-Ki,Cho, Sang-Rock,Kim, Hyun-Tae,Kim, Hea-Sook,Park, Hyun-Hee,Kim, Kwang-Ho 대한흉부심장혈관외과학회 1998 Journal of Chest Surgery (J Chest Surg) Vol.31 No.9
개심수술에서 Aprotinin에 의한 ACT가 연장되는가를 알아보기 위해 서로 다른 표면 촉매제인 kaolin (K-ACT)과 celite(C-ACT)를 이용하여 동시에 측정 비교하였다. 개심수술을 받은 22명의 성인을 대상으로 하여 Hemocron 8000 system을 이용하여 동시에 ACT를 측정 하였는데 aprotinin과 heparin 투여 전(Phase I), Aprotinin투여 후 heparin 투여 전(Phase II), heparin투여 5분 후(Phase III), haparin투여 30분 후(Phase IV), heparin투여 60분 후(Phase V), heparin투여 90분 후(Phase VI), protamin투여 30분 후(Phase VII)에 각각 측정하였다. Phase I, II, III에 두 군간에 차이가 없었으나 heparin투여 30분 후에는 C-ACT가 928$\pm$400초 K-ACT가 572$\pm$159초였고 60분 후에는 C-ACT가 888$\pm$254초 K-ACT가 535$\pm$186초 90분 후에는 C-ACT가 686$\pm$141초 K-ACT가 484$\pm$54초로 K-ACT에 비해 C-ACT가 통계학적으로 의의있게 증가하였다. 그러나 protamin투여 후에는 C-ACT가 137$\pm$26초 K-ACT가 139$\pm$28초로 두군간에 차이가 없었다. 이상의 결과에서 aprotinin투여 후 ACT는 연장이 되는 것이 아니라 activator로 celite를 사용했기 때문인 것으로 생각된다. 결론적으로 aprotinin을 투여한 개심수술에서 정확한 ACT수준을 측정하기 위하여 celite activator보다 kaolin activator를 사용해야 하며 heparin은 보통용량을 투입하여야 할 것으로 생각된다. Background: High-dose aprotinin has been reported to enhance the anticoagulant effects of heparin during cardiopulmonary bypass ; hence, som authors have advocated reducing the dose of heparin in patients treated with aprotinin. Material and Method: The ACT was measured before, during and after cardiopulmonary bypass, with Hemochron 801 system using two activators of celite(C-ACT) and kaolin(K- ACT) as surface activator. From June, 1996 to February, 1997, 22 adult patients who were scheduled for elective operation were enrolled in this study. Result: The ACT without heparin did not differ between C-ACT and K-ACT. At 30 minutes after anticoagulation with heparin and cardiopulmonary bypass, the average C-ACT was 928${\pm}$400 s; K-ACT was 572${\pm}$159s(p<0.05). After administration of protamine, C-ACT was 137${\pm}$26 s; K-ACT was 139${\pm}$28s, which were not statistically significant. Conclusion: Our results showed that the significant increase in the ACT during heparin- induced anticoagulation in the presence of aprotinin was due to the use of celite as surface activator, rather than due to enhanced anticoagulation of heparin by aprotinin. We conclude that the ACT measured with kaolin provides better monitoring of cardiac surgical patients treated with high dose aprotinin than does the ACT measured with celite. The patients treated with aprotinin should receive the usual doses of heparin.